Hepatitis C Virus Inactivation



Similar documents
Übertragung und Inaktivierung des Hepatitis C Virus

THE BURDEN OF NOROVIRUSES IN HEALTHCARE AND THE ROLE OF HIGH TOUCH SURFACES. Ben Lopman, MSc PhD

Hepatitis C Monitoring and Complications (and Treatment!) Dr Mark Douglas

Viral Safety of Plasma-Derived Products

Hepatitis C Vaccines: Are we making progress?

2.1.2 Characterization of antiviral effect of cytokine expression on HBV replication in transduced mouse hepatocytes line

Molecular Diagnosis of Hepatitis B and Hepatitis D infections

Biopharmaceutical Process Evaluated for Viral Clearance

HEPATITIS WEB STUDY Acute Hepatitis C Virus Infection: Epidemiology, Clinical Features, and Diagnosis

AUCUN CONFLIT D'INTERET

RealLine HCV PCR Qualitative - Uni-Format

Prospects for Vaccines against Hepatitis C Viruses. T. Jake Liang. M.D. Liver Diseases Branch NIDDK, NIH, HHS

AnDiaTec GmbH & Co. KG Leibnizstr Kornwestheim. Telefon Telefax

D Candotti. Institut National de la Transfusion Sanguine Dept. Agents Transmissibles par le Sang Paris, France

Hepatitis C Glossary of Terms

Dosaggi Sierologici e Molecolari nelle Epatiti B e C METODI MOLECOLARI. Ombretta Turriziani Dipartimento di Medicina Molecolare

Peg-IFN and ribavirin: what sustained virologic response can be achieved by using HCV genotyping and viral kinetics?

Case Finding for Hepatitis B and Hepatitis C

When an occupational exposure occurs, the source patient should be evaluated for both hepatitis B and hepatitis C. (AII)

Anti-Zona Pellucida Antibody Latex Agglutination Test

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP)

Instructions. Torpedo sirna. Material. Important Guidelines. Specifications. Quality Control

LIAISON XL HCV Ab Accurate diagnosis of the early stage of HCV infection

Test Facility Certification M.S. 85/2009

HBV Quantitative Real Time PCR Kit

Commonly Asked Questions About Chronic Hepatitis C

Review: How to work up your patient with Hepatitis C

Update on Hepatitis C. Sally Williams MD

Test Method for the Continuous Reduction of Bacterial Contamination on Copper Alloy Surfaces

CASL Symposium Hepatitis B Co-chairs: Carla Coffin and Mang Ma

HBV DNA < monitoring interferon Rx

Transfection reagent for visualizing lipofection with DNA. For ordering information, MSDS, publications and application notes see

Transmission of HCV in the United States (CDC estimate)

Viral Hepatitis Case Report

Preface. TTY: (888) or Hepatitis C Counseling and Testing, contact: 800-CDC-INFO ( )

Treatment of Acute Hepatitis C

Journal of Infectious Diseases Advance Access published September 24, Inactivation of Hepatitis C Virus Infectivity by Human Breast Milk

VIRAL SAFETY EVALUATION OF BIOTECHNOLOGY PRODUCTS DERIVED FROM CELL LINES OF HUMAN OR ANIMAL ORIGIN Q5A(R1)

3/25/2014. April 3, Dennison MM, et al. Ann Intern Med. 2014;160:

QuickTiter Hepatitis B Surface Antigen (HBsAg) ELISA Kit

National Health Burden of CLD in Italy

LAB 1 - Direct agglutination. Serology-the study of the in vitro reactions between antibody and antigen

Viral load testing. medical monitoring: viral load testing: 1

HCV in 2020: Any cases left? Rafael Esteban Hospital General Universitario Valle Hebron Barcelona. Spain

Guidance for Industry Antiviral Product Development Conducting and Submitting Virology Studies to the Agency

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. I. Requirements for Prior Authorization of Hepatitis C Agents

Animal Cell Culture. Third Edition. A Practical Approach OXJORD VNIVVRSITY 1'RVSS

Inactivation of Hepatitis C Virus Infectivity by Human Breast Milk

PRIOR AUTHORIZATION POLICY

QuickTiter FeLV Core Antigen ELISA Kit (FeLV p27)

Results Demographic profile of these children is shown in Table I.

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. I. Requirements for Prior Authorization of Hepatitis C Agents

Co-infected health-care workers

Genolution Pharmaceuticals, Inc. Life Science and Molecular Diagnostic Products

4A. Types of Laboratory Tests Available and Specimens Required. Three main types of laboratory tests are used for diagnosing CHIK: virus

Chapter 3. Immunity and how vaccines work

Guidance for Industry

boceprevir 200mg capsule (Victrelis ) Treatment naïve patients SMC No. (723/11) Merck Sharpe and Dohme Ltd

Non-clinical development of biologics

Expert Opinion. on the efficacy of. EndoDet and EndoDis + EndoAct. for cleaning and disinfection of. Olympus Gastroscope Type GIF-2T200.

TG1050, A NOVEL IMMUNOTHERAPEUTIC TO TREAT CHRONIC HEPATITIS B, CAN CONTROL HBsAg AND PROVOKE HBsAg SEROCONVERSION IN HBV-PERSISTENT MOUSE MODELS

Thrombin Generation Assay

Biotechnology and Recombinant DNA (Chapter 9) Lecture Materials for Amy Warenda Czura, Ph.D. Suffolk County Community College

NS5B Sequencing and Phenotypic Resistance Assays for HCV Subtypes 1a and 1b

Chapter 18: Applications of Immunology

Innovazione farmacologica e farmacologia clinica

bitter is de pil Linos Vandekerckhove, MD, PhD

ELISA BIO 110 Lab 1. Immunity and Disease

Generation of EBV-immortalized B cell lines

Boehringer Ingelheim- sponsored Satellite Symposium. HCV Beyond the Liver

Hepatitis C. Screening, Diagnosis and Linkage to Care

Analysis of the adaptive immune response to West Nile virus

Prevention of transmission of HIV and other bloodborne viruses in healthcare and post exposure prophylaxis. John Ferguson, UPNG 2012

PRIOR AUTHORIZATION PROTOCOL FOR HEPATITIS C TREATMENT

Fast, easy and effective transfection reagent for mammalian cells

Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis

HighPure Maxi Plasmid Kit

Hepatitis C. Eliot Godofsky, MD University Hepatitis Center Bradenton, FL

Quantitative HBV DNA measurements and the management of infected health care workers

Mir-X mirna First-Strand Synthesis Kit User Manual

12/2/2015 HEPATITIS B AND HEPATITIS C BLOOD EXPOSURE OBJECTIVES VIRAL HEPATITIS

Manufacturing process of biologics

Clinical Criteria for Hepatitis C (HCV) Therapy

The hepatitis C virus (HCV) is a single-stranded RNA virus of the Hepacivirus genus in the Flaviviridae family (Figure 2).

Didactic Series. Updated Post-Exposure Prophylaxis (PEP) Guidelines. Daniel Lee, MD UCSD Medical Center, Owen Clinic January 9, 2014

III III 0 II0 III II II 101 II I0I II 0I II

THE PREPARATION OF SINGLE DONOR CRYOPRECIPITATE

Monitoring of Treatment of viral hepatitis C

1) Siderophores are bacterial proteins that compete with animal A) Antibodies. B) Red blood cells. C) Transferrin. D) White blood cells. E) Receptors.

Cirrhosis and HCV. Jonathan Israel M.D.

Newly Diagnosed: HEPATITIS C. American Liver Foundation Support Guide

PRODUCT INFORMATION...

Geniron. Custom Antibody Services. Serum services Antibody Monoclonal. Purification Antibody Mono Y Genetic Immunization Genbody Polyclonal Antibody

The Epidemiology of Hepatitis A, B, and C

Mouse Insulin ELISA. For the quantitative determination of insulin in mouse serum and plasma

RealStar HBV PCR Kit /2012

Figure 4.1: Gel picture showing Generation of HIV-1subtype C codon optimized env expressing recombinant plasmid pvax-1:

HIV Drug resistanceimplications

Immunity and how vaccines work

New treatment options for HCV: implications for the Optimal Use of HCV Assays

Transcription:

Hepatitis C Virus Inactivation PD Dr. Eike Steinmann Centre for Experimental and Clinical Infection Research Institute of Experimental Virology, Twincore* *joint venture between Medical School Hannover and Helmholtz Centre for Infection Research

Hepatitis C Virus (HCV) Profile Family: Genus: Flaviviridae Hepacivirus E E Species: Hepatitis C virus (7 genotypes) Size: - nm Genome: (+) ssrna, ~9. kb Prevalence: Therapy: million patients next talk ss(+) RNA Nucleocapsid (core) Lipid membrane

Ways of HCV Transmissions drug abuse medical procedures i.v. drug abuse % sex % transfusions % unknown % transfusion sex vertical other

Virucidal testing using surrogate viruses testvirus surrogate-virus Hepatitis B Virus Duck hepatitis B virus (DHBV) Norovirus feline Calicivirus (FCV) murine Norovirus (MNV) Hepatitis C Virus bovine viral diarrhea virus (BVDV)

HCV infection system JFH/wt ΔE-E HCV RNA copies/well HCV RNA transcriptes In vitro Transcription T7-Polymerase amp NTR T7-Promotor Plasmid NTR Core E pfk-jfh E p7 NS HCV RNA NSB NSA NSA NSB NS transfection Detection infected cells (IFM, qrt-pcr) 9 h 7 h Huh7 hepatoma cells IFM Wakita and Pietschmann et al., Nat Med α NS

E - Mab Properties of cell culture-grown HCV particles Density peaks in sucrose gradient ca.. g/ml Spherical particles with diameter of ca. nm JFH wildtype Infectivity can be neutralized by CD8-specific antibodies Infectivity can be neutralized by Ig from patients and anti-e Mab Cell culture-grown HCV is infectious in vivo (chimp; chimeric mouse)

Virucidal efficacy of different alcohols against HCV Quantitative suspension: µl virus 9 µl disinfectant mix, incubation, mix titration infectivity (TCID /ml)

Log infectivity TCID /ml Log infectivity TCID /ml Effect of ethanol, -propanol and -propanol on HCV/BVDV HCV 8 7 8 7 ethanol -propanol -propanol contr. % % % % % contr. % % % % % detection limit incubation time min incubation time min BVDV 8 7 8 7 ethanol -propanol -propanol contr. % % % % % contr. % % % % % incubation time min incubation time min

Log RNA copies/ml Log infectivity TCID /ml HCV infectivity in comparison with HCV-RNA copy numbers HCV C, 7,, 8, days titration infectivity (TCID /ml) RNA isolation and quantification (qrt-pcr) 9 8 7 infectivity 7 8 days RNA copies RNA copies (x 7) RNA days RNA days 9 8 7 7 8 days

Log RLU/well Log infectivity TCID /ml HCV stability and inactivation in suspension 7 HCV 7 HCV HCV+Serum cytotoxicity 7 8 contr. 7 days undiluted, sec Ciesek et al. Journal of Infectious Diseases Steinmann et al. American Journal of Infection Control Steinmann et al. Antimicrobial Resistance and Infection Control

Log Infectivity TCID /ml Log Infectivity TCID /ml Establishment of a HCV carrier assay virusinoculum µl (drying) µl test substance 9 µl medium Ø FCS ( min vortex) (incubation for min) titration infectivity 7 suspension dried Control -propanol % -propanol ethanol Dörrbecker et al. Journal of Infectious Diseases

Log Infectivity TCID /ml Log Infectivity TCID /ml Survival of dried HCV on inanimate surfaces HCV cytotoxicity Control............% A B C D HCV - serum HCV + serum 7 8 days

Development of a drug transmission assay Log RLU/well 7 temperature in C In collaboration with NDRI, NY, USA Dr. Mateu-Gelabert, Prof. Hagan, Prof. Des Jarlais and Fixpunkt Hannover

Log Infectivity TCID /ml Log Infectivity TCID /ml Transmission of Hepatitis C virus among injecting drug users: viral stability and association with drug preparation equipment µl µl µl 8 µl. µl 8 8 days virus spike recovery concentrated plastic aluminium glass container material Dörrbecker et al. Journal of Infectious Diseases

Transmission of Hepatitis C virus among injecting drug users: viral stability and association with drug preparation equipment Dörrbecker et al. Journal of Infectious Diseases

Log infectivity ffu/ml HCV transmission by anaesthetica control propofol 7 8 days Gutelius et al. Gastroenterology Fischer et al. Clinical Infectious Diseases Steinmann et al. Clinical Infectious Diseases Behrendt et al. American Journal of Infection Control

Inactivation of HCV in blood products Steinmann et al. Transfusion

Inactivation kinetics of HCV in plasma by MB plus light treatment Steinmann et al. Transfusion

Inactivation kinetics of HCV by UVC irradiation of Platelet Concentrates Steinmann et al. Transfusion

Thermo-stability of seven Hepatitis C virus genotypes in vitro and in vivo Log Infectivity [TCID /ml] Log HCV RNA [IU/mL] a b a a a a a 7a 9 8 7 7 8 time [days] a b a a a a a 7a pool Dörrbecker et al. Journal of Viral Hepatitis

Inactivation of HCV in human mother s milk Pfaender et al. Journal of Infectious Diseases

Acknowledgement Twincore, Institute of Experimental Virology Dorothea Bankwitz Pathrick Behrendt Richard Brown Janina Brüning Patrick Chhatwal Anne Frentzen Gisa Gerold Sabine Giese Christina Grethe Sibylle Haid Kathrin Hüging Mandy Klaske Angga Kusuma Paula Perin Stephanie Pfänder Wiebke Rastedt Gabrielle Vieyres Stephanie Walter Kathrin Welsch Thomas Pietschmann Sandra Ciesek Martina Friesland Juliane Dörrbecker Nina Riebesehl Corinne Wilhelm Cooperations T. v. Hahn, M.P. Manns, H. Wedemeyer Hannover, Germany Joerg Steinmann Essen, Germany Philip Meuleman Ghent, Belgium Luis Schang, Che Colpitts Edmonton, Canada Peter Friebe Berkeley, USA Michael Diamond St Louis, USA Reagents: C. Rice New York, USA D. Moradpour Lausanne, Switzerland Funding: